Growth factors

Stimulating blood vessel formation with magnets

Wednesday, July 21, 2021 - 11:00pm

This was used to treat endothelial cells, stimulating blood vessel formation.

Key Points: 
  • This was used to treat endothelial cells, stimulating blood vessel formation.
  • "We developed a promising cell therapy alternative that can non-invasively stimulate blood vessel formation or regeneration through the application of an external low-intensity magnetic field."
  • These cells can change into different cell types, and also secrete a protein called VEGF-A that stimulates blood vessel formation.
  • Finally, VEGF-A extracts produced by magnet-treated mesenchymal stromal cells on gelatin increased blood vessel formation in a chick embryo, although further research is needed to confirm these results.

OncXerna Therapeutics to Present at The LifeSci Partners Private Company Summer Symposium

Monday, July 19, 2021 - 12:00pm

WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.

Key Points: 
  • WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.
  • OncXernas approach pairs those patients with OncXernas clinical-stage therapies and known mechanism of action that directly address these biologies, with the goal to substantially improve patient outcomes.
  • OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

BioCure Technology Inc. Announces Closing of Financing

Thursday, July 15, 2021 - 1:00am

The net proceeds from the non-brokered private placement are intended to be used for general working capital, research and development.

Key Points: 
  • The net proceeds from the non-brokered private placement are intended to be used for general working capital, research and development.
  • Biocure is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer.
  • Biocure, headquartered in Korea, has joint venture partners in Asia and Europe with planned clinical trials commencing in 2021.
  • Biocure is in the process of pre-clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim as well as Ranibizumab.

Global Erythropoietin Drugs Market to 2027 by Drug Class, Product, Application, Regional Outlook - ResearchAndMarkets.com

Wednesday, July 7, 2021 - 10:48am

The "Global Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global Erythropoietin Drugs Market size is expected to reach $20.2 billion by 2027, rising at a market growth of 11.8% CAGR.
  • The post-abbreviated new drug application (ANDA) is getting approvals and there is a high success rate of erythropoietin drugs in chemotherapy-induced anaemia.
  • Therefore, the impact of the COVID-19 pandemic is likely to have a positive impact on the erythropoietin drug market.

Chemotherapy Induced Neutropenia (CIN) Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

Wednesday, July 7, 2021 - 8:34am

The "Chemotherapy Induced Neutropenia (CIN) Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chemotherapy Induced Neutropenia (CIN) Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Chemotherapy Induced Neutropenia (CIN) Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the CIN, historical and forecasted epidemiology as well as the CIN market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • United States contributes to the major share of the Chemotherapy Induced Neutropenia (CIN) market as compared to other 7MM countries.
  • The current market of Chemotherapy Induced Neutropenia (CIN) is mainly covered by Neulasta, Neupogen, and their biosimilars.

2021 Report on TGF Beta Receptor Type 2 Drugs in Development - Featuring Auxagen, InteRNA Technologies and Velvio Among Others - ResearchAndMarkets.com

Tuesday, June 22, 2021 - 5:12pm

The "TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to this report TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) pipeline Target constitutes close to 7 molecules.
  • TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Transforming growth factor beta receptor II is a TGF beta receptor encoded by TGFBR2 gene.
  • It also reviews key players involved in TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects.

BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced

Tuesday, June 8, 2021 - 12:00pm

Compared to pegfilgrastim alone (n=110), the plinabulin and pegfilgrastim combination (n=111) showed decreased production of immature neutrophil band (p=0.0012), and decreased promyelocytes and myelocyte production (p=0.0488).

Key Points: 
  • Compared to pegfilgrastim alone (n=110), the plinabulin and pegfilgrastim combination (n=111) showed decreased production of immature neutrophil band (p=0.0012), and decreased promyelocytes and myelocyte production (p=0.0488).
  • Immature neutrophil band and promyelocytes and myelocytes are less functional defending against infection and have potentially deleterious immune suppression effects.
  • The Company has submitted New Drug Applications (NDA) for plinabulin in combination with pegfilgrastim as a treatment for the prevention of CIN for review in both the U.S. and China.
  • Treatment or prevention of CIN with G-CSF has been the standard of care since Neupogen was approved in 1991.

BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Onco

Monday, June 7, 2021 - 12:00pm

Chemotherapy-induced neutropenia continues to represent an unmet medical need despite the use of G-CSF, thus novel approaches are needed.

Key Points: 
  • Chemotherapy-induced neutropenia continues to represent an unmet medical need despite the use of G-CSF, thus novel approaches are needed.
  • The poster, titled Chemotherapy Induced Profound Neutropenia (PN) in Patients (pt) with Breast Cancer (BC) after chemotherapy and Plinabulin (Plin) plus Pegfilgrastim (Peg) Combination versus (vs) Peg Alone.
  • This is the first study to quantify physical wellbeing (pain and energy levels) of patients receiving plinabulin in combination with pegfilgrastim compared to pegfilgrastim alone.
  • We are very pleased to announce new positive clinical outcome data from the PROTECTIVE-2 Phase 3 program.

Global Anemia in Chronic Kidney Disease Analysis and Market Report 2021 - ResearchAndMarkets.com

Friday, June 4, 2021 - 10:19am

The "Disease Analysis: Anemia in Chronic Kidney Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Anemia in Chronic Kidney Disease" report has been added to ResearchAndMarkets.com's offering.
  • Biosimilars have also taken their toll, particularly in Europe, where biosimilar short-acting ESAs have taken a majority share of usage.
  • Iron is the other major anemia treatment, used for patients with iron deficiency from a potential multitude of causes associated with CKD.
  • Hence, they have the potential to take some market share from ESAs, as well as grow anemia treatment in non-dialysis CKD.

Spectrum Pharmaceuticals Announces That the ROLONTIS® (eflapegrastim) Pre-Approval Inspection Has Been Initiated

Tuesday, June 1, 2021 - 12:00pm

I would like to confirm that the FDA has initiated its inspection of the ROLONTIS manufacturing facility, said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals.

Key Points: 
  • I would like to confirm that the FDA has initiated its inspection of the ROLONTIS manufacturing facility, said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals.
  • ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs.
  • SPECTRUM PHARMACEUTICALS, INC. and ROLONTIS are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliate.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.